drug

memantine hydrochloride

Marketedupdated 2mo ago

by Polygen Pharmaceuticals Inc

Approved

community read0 votes

indications

investigational

Alzheimer's Disease

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 24, 2029

~2.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Sep 24, 2029patentUS 8039009*PED3.2y
Sep 24, 2029patentUS 8039009*PED3.2y
Sep 24, 2029patentUS 8039009*PED3.2y
Sep 24, 2029patentUS 8039009*PED3.2y
Mar 24, 2029method-of-use (U-539)US 80390092.7y
Mar 24, 2029method-of-use (U-539)US 80390092.7y
Mar 24, 2029method-of-use (U-539)US 80390092.7y
Mar 24, 2029method-of-use (U-539)US 80390092.7y

Data sources

ClinicalTrials.gov

last refreshed 2h ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying memantine hydrochloride

phase3Efficacy and Safety of DMB-I (INN: Latrepirdine) in Patients With Alzheimer Type Dementiarecruitingn=450